Cardiac Dimensions today said it raised another $15.2 million for its Carillon mitral valve implant, taking the total of its most recent funding round to $43 million.
The round included new investors Life Sciences Partners and Aperture Venture Partners, plus existing backers Lumira Capital, M.H. Carnegie & Co., and Arboretum Ventures.
Kirkland, Wash.-based Cardiac Dimensions said it plans to use the proceeds to fund the Reduce FMR study of the Carillon device, which it says is is the 1st blinded, randomized trial of a percutaneous mitral repair device in patients with functional mitral regurgitation.
"Coming from such a broad and experienced group of international investors, this investment represents an important endorsement of our technology and our team," CEO Rick Stewart said in prepared remarks. "With Reduce FMR on the verge of enrolling patients and a significant increase in our commercial activity, the completion of this financing allows us to aggressively pursue our goal to redefine the treatment of FMR for the benefit of the millions who suffer from its deleterious effects. Our investor syndicate is perfectly suited to partner with us in the execution of our clinical, commercial and geographical ambitions.”
Last year Cardiac Dimensions raised $20 million from a syndicate of international investors for the Carillon valve.
